<DOC>
	<DOCNO>NCT03016988</DOCNO>
	<brief_summary>Mantle cell lymphoma ( MCL ) type non-Hodgkin 's lymphoma ( NHL ) show poor survival . This study evaluate efficacy safety Bortezomib combine Fludarabine Cytarabine treatment naive relapse MCL eligible high dose therapy transplantation .</brief_summary>
	<brief_title>The Efficacy Safety Bortezomib Combined With Fludarabine Cytarabine Treatment Mantle Cell Lymphoma</brief_title>
	<detailed_description>The eligibility criterion pathologically confirm , previously untreated MCL relapse MCL define World Health Organization classification ; age≥18 year ; Eastern Cooperative Oncology Group ( ECOG ) performance status 0-2 ; adequate haematologic function ( haemoglobin &gt; 9.0 g/l , absolute neutrophil count &gt; 1500/ml , platelet &gt; 75,000/l ) , hepatic function ( total serum bilirubin ≤ 1.5 time upper limit normal , alanine aminotransferase aspartate aminotransferase ≤ 2.5 time upper limit normal ) , renal function ( serum creatinine ≤ 1.5 mg/dl , creatinine clearance ≥ 50 ml/min ) ; normal coagulation function electrocardiogram result . Stage define accord Ann Arbor system . The Fujian Medical University Union Hospital approve study subject enrol . Treatment dosages follow : day 1,4,8 , 11 subcutaneous infusion 1.3mg/m2 Bortezomib . Days 1-3 intravenous infusion 25mg/m2 Fludarabine . Days 1-3 intravenous infusion 500mg/m2 Cytarabine . The regimen repeat every 28 day maximum six cycle .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>1. pathologically confirm , previously untreated MCL relapse MCL define World Health Organization classification ; 2. age≥18 year ; 3 . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 ; 4. adequate haematologic function ( haemoglobin &gt; 9.0 g/l , absolute neutrophil count &gt; 1500/ml , platelet &gt; 75,000/l ) , 5. adequate hepatic function ( total serum bilirubin ≤ 1.5 time upper limit normal , alanine aminotransferase aspartate aminotransferase ≤ 2.5 time upper limit normal ) , 6. adequate renal function ( serum creatinine ≤ 1.5 mg/dl , creatinine clearance ≥ 50 ml/min ) ; 7. normal coagulation function electrocardiogram result . 8. willingness provide write informed consent . 1 . MCL patient NOT response refractory preview treatment . 2. Who NOT sign consent form . 3. whose life expectation le 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Mantle cell lymphoma</keyword>
	<keyword>Bortezomib</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Cytarabine</keyword>
</DOC>